Nach01 Foundation Model

AI foundation model for AI-native drug discovery, integrated with Microsoft Discovery and available via AWS Marketplace.

by Insilico Medicine · Drug Discovery AI

Executive Summary

Nach01 is an advanced AI foundation model developed by Insilico Medicine, specifically designed to revolutionize drug discovery and development. It is deeply integrated with Microsoft Discovery, enabling seamless AI-native drug discovery workflows that leverage cutting-edge artificial intelligence to accelerate research and development processes. This model primarily focuses on the chemistry aspect of drug discovery, utilizing natural language processing and generative AI capabilities to enhance the quality and efficiency of pharmaceutical research. Its availability through the AWS Marketplace further broadens its accessibility, allowing research organizations and pharmaceutical companies to easily adopt and integrate this powerful AI tool into their existing drug discovery pipelines.

Use Cases

  • Enabling AI-native drug discovery workflows
  • Accelerating hit identification and lead optimization in small molecule drug discovery
  • Improving productivity in pharmaceutical research and development
  • Leveraging natural language processing for chemistry-related research tasks
  • Streamlining drug target investigation and compound design

Features

Intelligence

  • AI-Native Drug Discovery: Enables end-to-end AI-driven workflows for accelerated drug discovery and development, from target identification to lead optimization.
  • Chemistry-Focused Generative AI: Utilizes advanced generative AI for designing and optimizing novel small molecules and chemical compounds with desired properties.
  • Natural Language Processing for Chemistry: Processes and interprets natural language queries and scientific texts to extract insights and facilitate research in chemical biology.

Technical Specifications

Architecture
Foundation model leveraging generative AI and NLP, integrated with Microsoft Discovery and deployed via AWS Marketplace for scalable access.
Deployment
SaaS
API Available
Yes

Infrastructure

  • AWS
  • Azure

AI/ML Stack

  • Generative AI
  • Natural Language Processing (NLP)
  • Machine Learning

Integrations

  • Microsoft Discovery

Pricing

Model
Subscription-based
Starting Price
Contact sales
Target Customer
Mid-Market,Enterprise

About Insilico Medicine

Insilico Medicine is a clinical-stage biotechnology company that leverages artificial intelligence and deep learning to accelerate drug discovery and development. The company focuses on therapeutic solutions for cancer, fibrosis, immunity, central nervous system diseases, and age-related conditions, utilizing its proprietary Pharma.AI platform to discover novel targets, design new molecules, and advance candidates into human clinical trials.

Founded: 2014 · Headquarters: Boston, Massachusetts, United States · Employees: 201-500 · Public